Compare NRP & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRP | NVAX |
|---|---|---|
| Founded | 2002 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | 1995 |
| Metric | NRP | NVAX |
|---|---|---|
| Price | $105.12 | $6.60 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $10.78 |
| AVG Volume (30 Days) | 29.9K | ★ 4.2M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.85% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 10.92 | 2.07 |
| Revenue | $218,701,000.00 | ★ $1,064,651,000.00 |
| Revenue This Year | N/A | $58.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.57 | ★ $3.19 |
| Revenue Growth | N/A | ★ 20.27 |
| 52 Week Low | $86.83 | $5.01 |
| 52 Week High | $113.03 | $11.55 |
| Indicator | NRP | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 55.36 | 38.44 |
| Support Level | $102.59 | $6.20 |
| Resistance Level | $105.42 | $7.03 |
| Average True Range (ATR) | 2.09 | 0.27 |
| MACD | 0.21 | 0.04 |
| Stochastic Oscillator | 64.38 | 35.32 |
Natural Resources Partners LP is a diversified natural resource company. It is engaged in the business of owning, managing and leasing a diversified portfolio of mineral properties in the United States, including interests in coal, trona and soda ash, crude oil and natural gas, construction aggregates, frac sand, and other natural resources. The company leases coal reserves to experience mine operators under long-term leases that grant the operator the right to mine its coal reserves in exchange for royalty payments. The company operates in two reportable segments namely: Mineral Rights and Soda Ash. the majority of the revenue is generated from the Mineral Rights segment. Geographically, the business activity of the group functions through the United States.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.